CEP-11981 is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CEP-11981’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CEP-11981 overview
CEP-11981 is under development for the treatment of metastatic prostate cancer, metastatic hormone-refractory (castration-resistant, androgen-independent) prostate cancer, adenocarcinoma of the prostate, neuroendocrine gastroenteropancreatic tumors and pancreatic cancer. The drug candidate is administered through oral route. It acts by targeting VEGFR-1, 2, 3 (vascular endothelial growth factor receptor) and TIE2 (tyrosine kinase with immunoglobulin-like and EGF-like domains 2) kinase and FGFR1. It was also under development for the treatment of solid tumors and urothelial carcinoma (UC).
Teva Pharmaceutical Industries overview
Teva Pharmaceutical Industries (Teva) discovers, develops, manufactures, and commercializes generic and specialty medicines. The company provides specialty medicines to treat disorders of the central nervous system (CNS), cancer, respiratory, dermatology, women’s health, and other disease conditions. It offers generic medicines in a range of dosage forms including capsules, tablets, injectables, liquids, inhalants, creams, and ointments. Teva also provides over-the-counter (OTC) products, besides active pharmaceutical ingredients (APIs). It also focuses on developing generic drugs. The company conducts its worldwide operations through a network of subsidiaries in regions such as North America, Europe, and International Markets. Teva is headquartered in Tel Aviv, Israel.
For a complete picture of CEP-11981’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.